NexImmune (NEXI) Competitors $0.0002 0.00 (0.00%) As of 08/18/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock NEXI vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXWShould you be buying NexImmune stock or one of its competitors? The main competitors of NexImmune include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), ARAVIVE (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry. NexImmune vs. Its Competitors 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech ARAVIVE Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics 180 Life Sciences (NASDAQ:ATNFW) and NexImmune (NASDAQ:NEXI) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability. Which has stronger valuation & earnings, ATNFW or NEXI? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/ANexImmuneN/AN/A-$32.34M-$18.540.00 Does the media refer more to ATNFW or NEXI? In the previous week, 180 Life Sciences had 3 more articles in the media than NexImmune. MarketBeat recorded 3 mentions for 180 Life Sciences and 0 mentions for NexImmune. 180 Life Sciences' average media sentiment score of 0.80 beat NexImmune's score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Overall Sentiment 180 Life Sciences Positive NexImmune Neutral Do institutionals & insiders hold more shares of ATNFW or NEXI? 9.9% of NexImmune shares are held by institutional investors. 14.9% of NexImmune shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is ATNFW or NEXI more profitable? 180 Life Sciences' return on equity of 0.00% beat NexImmune's return on equity.Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A NexImmune N/A -534.32%-213.72% Summary180 Life Sciences beats NexImmune on 4 of the 6 factors compared between the two stocks. Get NexImmune News Delivered to You Automatically Sign up to receive the latest news and ratings for NEXI and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEXI vs. The Competition Export to ExcelMetricNexImmunePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$806.58M$5.76B$9.65BDividend YieldN/A4.84%3.91%4.09%P/E Ratio0.001.1530.7825.12Price / SalesN/A25.87456.64116.46Price / CashN/A19.5625.2228.45Price / Book0.006.609.375.95Net Income-$32.34M-$4.93M$3.26B$265.46M7 Day PerformanceN/A0.05%1.88%0.96%1 Month PerformanceN/A-0.11%3.73%2.47%1 Year PerformanceN/A21.07%28.93%20.24% NexImmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEXINexImmuneN/A$0.00flatN/AN/A$0.00N/A0.006ATNFW180 Life SciencesN/A$0.11+830.7%N/A+4,958.8%$0.00N/A0.007Gap DownHigh Trading VolumeLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.01flatN/AN/A$0.00N/A0.002AIMDWAinosN/A$0.43-4.0%N/AN/A$0.00$106.21K0.0040News CoverageALVOWAlvotechN/A$1.41+6.0%N/A-64.1%$0.00$585.60M0.004Positive NewsGap UpHigh Trading VolumeARAVARAVIVEN/A$0.04flatN/AN/A$0.00$9.14M0.0020High Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.04-30.8%N/AN/A$0.00N/A0.0015Gap DownBFRIWBiofronteraN/A$0.14flatN/A+165.2%$0.00$38.00M0.0070Positive NewsBTMDWbioteN/A$0.01+21.0%N/A-97.9%$0.00$199.07M0.00N/AGap UpHigh Trading VolumeBCTXWBriaCell TherapeuticsN/A$0.03-5.1%N/A-85.2%$0.00N/A0.008Positive News Related Companies and Tools Related Companies 180 Life Sciences Competitors 4D pharma Competitors Aesther Healthcare Acquisition Competitors Ainos Competitors Alvotech Competitors ARAVIVE Competitors Atlantic Coastal Acquisition Corp. II Competitors Biofrontera Competitors biote Competitors BriaCell Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NEXI) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NexImmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NexImmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access